- Home
- » Tags
- » Spinal muscular atrophy
Top View
- Spinal Muscular Atrophy
- (ALS) and Spinal Muscular Atrophy (SMA): a Genetic Linkage? Michael Groden Michael Will Graduate in June 2015 with an Honors Biology B.S
- Landscape of Spinal Muscular Atrophy Newborn Screening in the United States: 2018–2021
- Spinal Muscular Atrophy (SMA) Novartis and Avexis Combine, Aiming to Transform the Care of SMA, the #1 Genetic Cause of Infant Mortality1
- Increased Chitotriosidase 1 Concentration Following Nusinersen
- What You Need to Know About Carrier Testing
- Migraine Is Associated with Increased Risk of Perioperative
- Differentiating Lower Motor Neuron Syndromes
- Spinal Muscular Atrophy Associated with Progressive Myoclonus Epilepsy
- New Roche Data at the 2019 AAN Annual Meeting Showcase Breadth
- Polio-Like Deformity: a Diagnostic Dilemma
- Metabolic and Nutritional Issues Associated with Spinal Muscular Atrophy
- Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment with Nusinersen
- Increased Chitotriosidase1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy
- SMA with Progressive Myoclonic Epilepsy (SMA-PME)
- Reference ID: 4625921 FULL PRESCRIBING INFORMATION
- Neurology Clerkship Review
- Disease Course and Prognostic Factors of Progressive Muscular Atrophy
- Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy
- Spinraza (Nusinersen): Reports of Communicating Hydrocephalus Not
- Intone Year Experience with Spinraza in Spinal Muscular Atrophy
- Nusinersen in Adult Patients with 5Q Spinal Muscular Atrophy: a Multicenter
- Challenges and Opportunities in Clinical Trials for Spinal Muscular Atrophy
- Comparing Axonal Excitability in Past Polio to Amyotrophic Lateral Sclerosis
- Late-Onset Neurodegenerative Diseases—The Role of Protein Insolubility
- Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing
- Diseases of the Nervous System G11.0 – G24.02
- Prescribing Information
- SMN Deficiency in Severe Models of Spinal Muscular Atrophy Causes
- Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5Q-Spinal Muscular Atrophy Patients
- Polyarticular Arthritis and Spinal Muscular Atrophy in Acid Ceramidase Deficiency Hooi Ling Teoh, MBBS, FRACP,A, B Alexander Solyom, MD,C Edward H
- Facts About Spinal Muscular Atrophy
- SMA) in the Province of Saskatchewan Gain Access to SPINRAZA™ (Nusinersen)
- Metabolic Dysfunction in Spinal Muscular Atrophy
- Post-Polio Syndrome
- Monday, 13 May 2019
- Treatment Options in Motor Neuron Disease: Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy
- Spinraza, INN-Nusinersen
- Chronic Spinal Muscular Atrophy
- New and Developing Therapies in Spinal Muscular Atrophy: from Genotype to Phenotype to Treatment and Where Do We Stand?
- Treatment for Neurological Disorder Could Be Repurposed For
- Sma Spinal Muscular Atrophy
- The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy
- Newborn Screening and Spinal Muscular Atrophy
- Spinal Muscular Atrophy (SMA)
- New Data at AAN Reinforce Novartis Commitment to Transforming the Lives of People of All Ages Who Live with Neurological Conditions
- Spinal Muscular Atrophy in Adults
- Parkinson Disease: Can Tdcs Enhance the Benefits of Physical
- Spinal Muscular Atrophy: Huge Steps
- Cognitive Performance of Patients with Adult 5Q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis
- COMMENTARY Feline Spinal Muscular Atrophy
- Nusinersen Treatment of Spinal Muscular Atrophy – a Systematic Review
- Spinal and Bulbar Muscular Atrophy - Clinical Features and Pathogenesis